---
title: "Dihexa"
slug: "dihexa"
type: "compound"
category: "Cognitive"
url: "https://peptidesciencethailand.com/compounds/dihexa"
description: "A hexapeptide that potentiates HGF/c-Met signaling and has shown synaptogenic activity in preclinical models. Nootropic research profile and mechanism detail."
---
# Dihexa

*Hexapeptide Analog, Potent Hepatocyte Growth Factor Pathway Modulator*

**Category:** Cognitive  
**Format:** Lyophilized Vial  
**Amount:** 10mg  
**Purity:** >99% (HPLC)

## Overview

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic hexapeptide analog of angiotensin IV developed by researchers at Washington State University under the direction of Dr. Joseph Harding and Dr. John Wright. It was designed as a stable, metabolically resistant analog of the endogenous hexapeptide Nle1-angiotensin IV, incorporating specific structural modifications to enhance receptor binding potency and oral bioavailability. Dihexa represents one of the most potent nootropic compounds identified in preclinical neuroscience research, demonstrating cognitive-enhancing effects at notably low doses in animal models.

The primary mechanism of action of Dihexa centers on its ability to potentiate the hepatocyte growth factor (HGF)/c-Met receptor signaling pathway in the central nervous system. Unlike many nootropic compounds that modulate neurotransmitter systems directly, Dihexa enhances synaptogenic signaling, the molecular process by which new synaptic connections are formed between neurons. Research published in the Journal of Pharmacology and Experimental Therapeutics demonstrated that Dihexa functions as an allosteric modulator of the HGF/c-Met receptor system, dramatically amplifying the neurotrophic signaling initiated by hepatocyte growth factor binding to its c-Met receptor tyrosine kinase.

Hepatocyte Growth Factor, despite its name, plays critical roles in the central nervous system extending far beyond hepatic biology. In the brain, HGF acts as a potent neurotrophic factor that promotes neuronal survival, neurite outgrowth, and synaptogenesis through c-Met receptor activation. The c-Met receptor is a transmembrane receptor tyrosine kinase expressed on neurons, particularly in cortical and hippocampal regions essential for learning and memory formation. When activated by HGF, c-Met initiates the Ras/MAPK and PI3K/Akt signaling cascades, driving gene expression programs that support dendritic spine formation, synaptic strengthening, and long-term potentiation (LTP), the cellular substrate of memory formation.

Dihexa's extraordinary potency stems from its mechanism of facilitating HGF/c-Met dimerization. In the normal physiological process, HGF must bind to two c-Met receptor molecules to induce receptor dimerization and subsequent transphosphorylation, which activates the intracellular signaling cascade. Dihexa stabilizes the HGF/c-Met complex, lowering the threshold concentration of HGF required to achieve effective receptor dimerization and activation. This allosteric potentiation mechanism means that Dihexa amplifies existing neurotrophic signaling rather than creating pharmacological effects through an entirely exogenous pathway.

In preclinical studies, Dihexa demonstrated remarkable cognitive-enhancing properties at doses approximately seven orders of magnitude lower than brain-derived neurotrophic factor (BDNF). Research conducted by Benoist et al. (2014) and published in the Journal of Pharmacology and Experimental Therapeutics showed that Dihexa reversed scopolamine-induced cognitive deficits in rats at picomolar concentrations when applied to hippocampal slice preparations. In vivo studies demonstrated that both intracerebroventricular and oral administration of Dihexa improved performance in spatial learning tasks, including the Morris water maze and Barnes maze paradigms commonly used to assess hippocampal-dependent memory function.

The synaptogenic effects of Dihexa have been directly visualized through confocal microscopy studies examining dendritic spine morphology. Treatment with Dihexa significantly increased the density and size of dendritic spines on hippocampal neurons, consistent with enhanced synaptic connectivity. Electrophysiological recordings confirmed that these morphological changes correspond to functional synaptic strengthening, with Dihexa-treated preparations exhibiting enhanced long-term potentiation at Schaffer collateral-CA1 synapses in the hippocampus.

A significant advantage of Dihexa relative to many peptide-based compounds is its demonstrated oral bioavailability. The incorporation of the hexanoic acid moiety and aminohexanoic amide modifications confers lipophilicity sufficient for gastrointestinal absorption and blood-brain barrier penetration. Studies confirmed that oral administration produces cognitive effects comparable to direct central administration, suggesting effective peripheral-to-central distribution. This oral bioavailability distinguishes Dihexa from most peptide therapeutics, which typically require parenteral administration.

Dihexa's selectivity for the HGF/c-Met pathway rather than broad neurotransmitter modulation represents a fundamentally different approach to cognitive enhancement. By targeting the synaptogenic machinery directly, Dihexa promotes structural neuroplasticity, the physical formation of new synaptic connections, rather than simply modulating the efficiency of existing neurotransmission. This mechanism has generated significant research interest in the context of age-related cognitive decline and neurodegenerative conditions characterized by progressive synaptic loss.

Safety and pharmacological characterization of Dihexa remains in early stages, and the compound has not entered formal clinical trials. The potency of its effects on growth factor signaling pathways necessitates careful investigation of potential off-target effects, particularly regarding cellular proliferation pathways that share downstream signaling elements with the HGF/c-Met system. Ongoing preclinical research continues to define the pharmacokinetic profile, therapeutic window, and safety parameters essential for translational development.

## Mechanism of Action

### Step 1: HGF/c-Met Complex Stabilization

Dihexa acts as an allosteric modulator that stabilizes the hepatocyte growth factor (HGF)/c-Met receptor complex, facilitating receptor dimerization at lower HGF concentrations than would otherwise be required for effective signaling activation.

### Step 2: c-Met Receptor Transphosphorylation

Stabilized receptor dimerization triggers c-Met tyrosine kinase transphosphorylation, activating the intracellular docking sites that recruit downstream signaling adaptors including Gab1, Grb2, and SOS to the activated receptor complex.

### Step 3: Ras/MAPK & PI3K/Akt Cascade Activation

Recruited adaptor proteins initiate parallel Ras/MAPK (ERK1/2) and PI3K/Akt signaling cascades. ERK pathway activation drives immediate early gene expression (c-Fos, Arc), while Akt signaling promotes neuronal survival through phosphorylation of pro-apoptotic substrates.

### Step 4: Synaptogenic Gene Expression

Converging MAPK and Akt signals activate CREB-dependent transcription of synaptic plasticity genes, including those encoding postsynaptic density proteins (PSD-95), glutamate receptor subunits, and structural proteins required for dendritic spine formation and stabilization.

### Step 5: Dendritic Spine Formation & LTP Enhancement

Upregulated synaptic protein expression drives the formation of new dendritic spines and the enlargement of existing spines in hippocampal and cortical neurons, corresponding to enhanced long-term potentiation (LTP) and strengthened synaptic connectivity underlying memory formation.

## Researched Benefits

### Synaptogenic Neurotrophic Activity

Dihexa promotes the physical formation of new synaptic connections through HGF/c-Met pathway potentiation. Confocal microscopy studies demonstrate increased dendritic spine density and size in hippocampal neurons, while electrophysiological recordings confirm functional synaptic strengthening and enhanced long-term potentiation.

### Cognitive Enhancement at Low Doses

Preclinical research demonstrates cognitive-enhancing effects at notably low concentrations, approximately seven orders of magnitude more potent than BDNF in promoting synaptogenesis. Animal studies show improved performance in hippocampal-dependent spatial learning and memory tasks following both central and oral administration.

### Oral Bioavailability

Unlike most peptide-based compounds, Dihexa demonstrates oral bioavailability due to its modified structure incorporating lipophilic hexanoic acid and aminohexanoic amide groups. Studies confirm that oral administration achieves cognitive effects comparable to direct central nervous system administration, suggesting effective blood-brain barrier penetration.

### Structural Neuroplasticity Promotion

By targeting synaptogenic signaling rather than neurotransmitter modulation, Dihexa promotes structural neuroplasticity, the physical remodeling of neural circuits through new synapse formation. This mechanism addresses synaptic connectivity directly, a fundamentally different approach from compounds that modulate existing neurotransmission efficiency.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 10-20mg per day orally, or 0.5-1mg per day via subcutaneous injection based on preclinical research protocols |
| Route | Oral or subcutaneous injection |
| Duration | Research protocols typically span 4-8 weeks |
| Cycle Notes | Due to the early stage of Dihexa research, established cycling protocols are limited. Preclinical studies have used continuous administration periods of varying duration without reported tolerance development. Rest periods between cycles are generally recommended. |
| Reconstitution | For injectable preparation, reconstitute lyophilized powder with bacteriostatic water. Using a 10mg vial with 1mL bacteriostatic water yields 10mg/mL concentration. Store reconstituted solution refrigerated at 2-8C and use within 21 days. |

> **Specialist note:** A your specialist should evaluate neurological status, cognitive baseline, and medical history before initiating a Dihexa protocol. Due to the compound's potent effects on growth factor signaling pathways, thorough assessment including evaluation of any conditions involving aberrant cellular proliferation is essential.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 10mg per vial |
| Purity | >99% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Composition | N-hexanoic-Tyr-Ile-(6) aminohexanoic amide |
| Molecular Weight | 507.63 g/mol |
| Storage | Store lyophilized powder at -20C. Reconstituted solution at 2-8C. Protect from light. |
| Appearance | White to off-white lyophilized powder |

## Medical Guidance

Dihexa is a potent modulator of the HGF/c-Met growth factor receptor pathway, which has implications for cellular proliferation and survival signaling in addition to its neurotrophic effects. A specialist should conduct a thorough medical evaluation before initiating any Dihexa protocol, with particular attention to conditions involving growth factor pathway dysregulation. The compound remains in preclinical research stages and has not been evaluated in formal human clinical trials.

## Frequently Asked Questions

### What is Dihexa and how was it developed?

Dihexa is a synthetic hexapeptide analog of angiotensin IV developed at Washington State University by Drs. Harding and Wright. It was designed as a metabolically stable analog of the endogenous peptide Nle1-angiotensin IV, with structural modifications to enhance receptor binding potency and oral bioavailability. The compound was specifically engineered to potentiate hepatocyte growth factor (HGF) signaling in the central nervous system.

### How does Dihexa differ from other nootropic compounds?

Unlike most nootropic compounds that modulate neurotransmitter systems (acetylcholine, dopamine, glutamate), Dihexa targets the synaptogenic machinery directly through HGF/c-Met pathway potentiation. This promotes structural neuroplasticity, the physical formation of new synaptic connections, rather than simply modulating the efficiency of existing neurotransmission. This mechanistic distinction represents a fundamentally different approach to cognitive enhancement.

### Can Dihexa be taken orally?

Yes. Unlike most peptide-based compounds that require injection due to gastrointestinal degradation, Dihexa demonstrates oral bioavailability. Its modified structure incorporating lipophilic hexanoic acid groups enables gastrointestinal absorption and blood-brain barrier penetration. Preclinical studies have confirmed that oral administration produces cognitive effects comparable to direct central nervous system delivery.

### What stage of research is Dihexa currently in?

Dihexa remains in preclinical research stages. Published studies have been conducted primarily in rodent models, demonstrating cognitive-enhancing effects in spatial learning and memory paradigms. The compound has not entered formal human clinical trials. Safety profiling, pharmacokinetic characterization, and dose-response studies continue in laboratory settings to establish the foundation for potential translational development.

### Is medical supervision necessary for Dihexa?

Yes. Dihexa's potent effects on the HGF/c-Met growth factor signaling pathway require careful medical evaluation before use. A specialist must assess neurological status, medical history, and any conditions involving growth factor pathway dysregulation. The compound's influence on cellular proliferation and survival signaling pathways necessitates informed medical oversight throughout any research protocol.

## Related Compounds

- /compounds/semax
- /compounds/noopept
- /compounds/cerebrolysin